ACADIA Pharmaceuticals (ACAD)
ACADIA Pharmaceuticals Revenue Growth: 3.45%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ACAD Revenue Growth Rankings
| Overall | 41st percentile | 2575 of 4399 |
| Sector | 35th percentile | 297 of 461 in Healthcare |
| Industry | 41st percentile | 74 of 126 in Biotechnology |
ACAD Revenue Growth Range, Past 5 Years
| Minimum | -98.34% | Dec 2011 |
| Maximum | 1900% | Dec 2010 |
| Average | 191.4% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these ACAD related companies
ACAD News
$ACAD she's gonna blow! I remember a month or two ago she went from $1.50 to $2.25 in 3 or 4 days
about 8 days ago by oliveblakcok
about 8 days ago by oliveblakcok
ACADIA Pharmaceuticals to Webcast Educational Program on Parkinson’s Disease Psychosis on May 22, 2012
May 15, 9:00AM Business Wire
May 15, 9:00AM Business Wire
$ACAD http://stks.co/3oVo Price consolidation & Volatility squeeze, Bollinger bands get very close, positive momentum
about 9 days ago by gantosj
about 9 days ago by gantosj
$ACAD I also grabbed from CC there will be a 5/22 primavision presentation in nyc and live webcast for analyst
about 14 days ago by oliveblakcok
about 14 days ago by oliveblakcok
ACADIA Pharmaceuticals to Announce First Quarter 2012 Financial Results on May 8, 2012
May 01, 9:00AM Business Wire
May 01, 9:00AM Business Wire
$ACAD forms bullish "Continuation Wedge" chart pattern. http://stks.co/3Yvy
about 25 days ago by RecogniaEvents
about 25 days ago by RecogniaEvents
$ACAD http://stks.co/39d7 in a few here 2.19 flagging here for days. looks ready
about 54 days ago by kunal00
about 54 days ago by kunal00
ACADIA Pharmaceuticals to Present at the 11th Annual Needham Healthcare Conference on April 3, 2012
Mar 28, 9:00AM Business Wire
Mar 28, 9:00AM Business Wire
$ACAD http://stks.co/36y8 pivotal data out in few months for this #BIOTECH, last time spiked to 6$ - $ACAD
about 56 days ago by LTbioinvestor
about 56 days ago by LTbioinvestor
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2011
Mar 06, 4:01PM Business Wire
Mar 06, 4:01PM Business Wire
ACADIA Pharmaceuticals Announces Extension of Drug Discovery Collaboration with Allergan, Inc.
Mar 05, 9:00AM Business Wire
Mar 05, 9:00AM Business Wire
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2011 Financial Results on March 6, 2012
Feb 28, 9:00AM Business Wire
Feb 28, 9:00AM Business Wire
ACADIA Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference on February 13, 2012
Feb 06, 9:00AM Business Wire
Feb 06, 9:00AM Business Wire
ACADIA Pharmaceuticals Announces Election of Bill Wells to Its Board of Directors
Jan 30, 9:00AM Business Wire
Jan 30, 9:00AM Business Wire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ACAD | 1.39 | +0.00 | +0.00% | 73.53M |
